Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 11, 2024
Product Development
AbbVie’s schizophrenia miss: implications for itself, BMS and M4 pipeline
Price tag of AbbVie’s Cerevel deal now harder to justify, as BMS’s first-mover advantage extends and M4 PAMs come into question
BioCentury | Dec 6, 2023
Deals
Building again outside immunology, AbbVie buys Cerevel for $8.7B
On heels of ImmunoGen deal, pharma looks to Pfizer spinout led by Coles, Renaud to add neuroscience candidates nearing clinical readouts
BioCentury | May 3, 2023
Management Tracks
Culture and trust: How Cerevel’s Coles picked Renaud for CEO
Ahead of handful of milestones, former Translate Bio, Idenix CEO joining CNS company; Coles retaining chairman role
BioCentury | Apr 28, 2022
Discovery & Translation
Howard University’s equity focus advances translation, invites industry
The HBCU’s research creates opportunities in dermatology, oncology and neuropsychiatry
BioCentury | Dec 24, 2019
Company News
Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines
BioCentury | Apr 11, 2019
Clinical News
Cerevel's GABA A modulator reduces photosensitivity in epilepsy patients
BioCentury | Oct 26, 2018
Finance
Springing into Cerevel
Why Bain and Pfizer reunited to launch neuroscience spinout Cerevel
Items per page:
1 - 7 of 7